Bristol Sacrifices Part Of Indication For Kidney Transplant Drug Belatacept
Executive Summary
Bristol-Myers Squibb is willing to tailor the patient population for its kidney transplant agent belatacept by selecting for a biomarker and limit use by recommending the less intensive treatment regimen to try and avoid the risk of post-transplant lymphoproliferative disorder that was seen in clinical trials
You may also be interested in...
Endpoints For Kidney Transplant Drugs Getting FDA Attention
The agency will conduct a two-day workshop in September to hear from health care providers, academia and industry on potential clinical or surrogate endpoints and biomarkers for clinical trials of drugs for kidney transplant patients.
Bristol's Kidney Transplant Drug Belatacept Finally Approved
Large patient registry will help keep tabs on risk for post-transplant lymphoproliferative disorder.
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result